CRDL News

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart Ready to Announce with Confidence?

Cardiol Therapeutics Announces Year-End 2025 Update on Operations Ready to Announce with Confidence?

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference Ready to Announce with Confidence?

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure Ready to Announce with Confidence?

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million Ready to Announce with Confidence?

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million Ready to Announce with Confidence?

Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million Ready to Announce with Confidence?

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis Ready to Announce with Confidence?